Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of LH011 plus gemcitabine and nab-paclitaxel in advanced pancreatic cancer
ChiCTR2300069010Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of upamostat in pancreatic cancer (PC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: overall survival and safety and tolerability. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
upamostat
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2300069010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069010.